

# Trial Intelligence Report - TS-5157

## Protocol Summary

Indication:	General
Phase:	Follow-up Days -28 to -1 Baseline Day 0 Wk 1 Day 7 Wk 4 Day 28 Wk 8 Day 56 W
Sample Size:	108
Duration (weeks):	30
Dropout Rate:	24.3%
Primary Endpoint:	Frequency of moderate to severe adverse events through Week 24 by dosing level, freq

## Success Prediction

52.3%

Assessment: Moderate probability of success

## Strategic Recommendations

1. Consider increasing sample size if feasible.
2. Implement robust retention strategies to reduce dropout.
3. Review endpoint selection and measurement timing.

